These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

484 related articles for article (PubMed ID: 32014868)

  • 1. Advances in the Treatment of Acute Myeloid Leukemia: New Drugs and New Challenges.
    Short NJ; Konopleva M; Kadia TM; Borthakur G; Ravandi F; DiNardo CD; Daver N
    Cancer Discov; 2020 Apr; 10(4):506-525. PubMed ID: 32014868
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Apoptosis targeted therapies in acute myeloid leukemia: an update.
    Ball S; Borthakur G
    Expert Rev Hematol; 2020 Dec; 13(12):1373-1386. PubMed ID: 33205684
    [No Abstract]   [Full Text] [Related]  

  • 3. Emerging agents and regimens for AML.
    Liu H
    J Hematol Oncol; 2021 Mar; 14(1):49. PubMed ID: 33757574
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protein Kinase Inhibitors as Therapeutic Drugs in AML: Advances and Challenges.
    Ling Y; Zhang Z; Zhang H; Huang Z
    Curr Pharm Des; 2017 Nov; 23(29):4303-4310. PubMed ID: 28671056
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Precision therapy for acute myeloid leukemia.
    Yang X; Wang J
    J Hematol Oncol; 2018 Jan; 11(1):3. PubMed ID: 29301553
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identifying effective drug combinations for patients with acute myeloid leukemia.
    Yilmaz M; Kadia T; Ravandi F
    Expert Rev Anticancer Ther; 2020 Jul; 20(7):591-601. PubMed ID: 32552126
    [TBL] [Abstract][Full Text] [Related]  

  • 7. What are the most promising new agents in acute myeloid leukemia?
    Sallman DA; Lancet JE
    Curr Opin Hematol; 2017 Mar; 24(2):99-107. PubMed ID: 28030373
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CPX-351 in acute myeloid leukemia: can a new formulation maximize the efficacy of old compounds?
    Brunetti C; Anelli L; Zagaria A; Specchia G; Albano F
    Expert Rev Hematol; 2017 Oct; 10(10):853-862. PubMed ID: 28814164
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting acute myeloid leukemia with TP53-independent vosaroxin.
    Benton CB; Ravandi F
    Future Oncol; 2017 Jan; 13(2):125-133. PubMed ID: 27615555
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic biomarkers of drug resistance: A compass of prognosis and targeted therapy in acute myeloid leukemia.
    Long L; Assaraf YG; Lei ZN; Peng H; Yang L; Chen ZS; Ren S
    Drug Resist Updat; 2020 Sep; 52():100703. PubMed ID: 32599434
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Two decades of targeted therapies in acute myeloid leukemia.
    Cucchi DGJ; Polak TB; Ossenkoppele GJ; Uyl-De Groot CA; Cloos J; Zweegman S; Janssen JJWM
    Leukemia; 2021 Mar; 35(3):651-660. PubMed ID: 33589753
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New treatment for acute myelogenous leukemia.
    DiNardo CD; Cortes JE
    Expert Opin Pharmacother; 2015 Jan; 16(1):95-106. PubMed ID: 25480777
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Secondary AML Emerging After Therapy with Hypomethylating Agents: Outcomes, Prognostic Factors, and Treatment Options.
    Richardson DR; Green SD; Foster MC; Zeidner JF
    Curr Hematol Malig Rep; 2021 Feb; 16(1):97-111. PubMed ID: 33609248
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cell cycle inhibitors for the treatment of acute myeloid leukemia: a review of phase 2 & 3 clinical trials.
    Jammal N; Rausch CR; Kadia TM; Pemmaraju N
    Expert Opin Emerg Drugs; 2020 Dec; 25(4):491-499. PubMed ID: 33161749
    [No Abstract]   [Full Text] [Related]  

  • 15. Targeting Tyrosine Kinases in Acute Myeloid Leukemia: Why, Who and How?
    Fernandez S; Desplat V; Villacreces A; Guitart AV; Milpied N; Pigneux A; Vigon I; Pasquet JM; Dumas PY
    Int J Mol Sci; 2019 Jul; 20(14):. PubMed ID: 31336846
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel and emerging drugs for acute myeloid leukemia.
    Stein EM; Tallman MS
    Curr Cancer Drug Targets; 2012 Jun; 12(5):522-30. PubMed ID: 22483153
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted therapies in Acute Myeloid Leukemia: a focus on FLT-3 inhibitors and ABT199.
    Naqvi K; Konopleva M; Ravandi F
    Expert Rev Hematol; 2017 Oct; 10(10):863-874. PubMed ID: 28799432
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted therapy of acute myeloid leukemia.
    Carneiro BA; Altman JK; Kaplan JB; Ossenkoppele G; Swords R; Platanias LC; Giles FJ
    Expert Rev Anticancer Ther; 2015 Apr; 15(4):399-413. PubMed ID: 25623136
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cyclin-dependent kinase (CDK) 9 and 4/6 inhibitors in acute myeloid leukemia (AML): a promising therapeutic approach.
    Lee DJ; Zeidner JF
    Expert Opin Investig Drugs; 2019 Nov; 28(11):989-1001. PubMed ID: 31612739
    [No Abstract]   [Full Text] [Related]  

  • 20. Acute myeloid leukemia: Therapy resistance and a potential role for tetraspanin membrane scaffolds.
    Floren M; Gillette JM
    Int J Biochem Cell Biol; 2021 Aug; 137():106029. PubMed ID: 34174403
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.